Calypso Biotech, a clinical-stage spin-off from Merck Serono, develops therapeutic biologics that targets Interleukin-15 (IL-15). Its lead product is a best-in-class anti-IL-15 antibody CALY-002 for auto-immune diseases, currently in Phase 1 trial.
Acquired by Novartis in 2024.